13.75
price up icon3.31%   0.44
after-market Dopo l'orario di chiusura: 13.75
loading
Precedente Chiudi:
$13.31
Aprire:
$13.21
Volume 24 ore:
460.79K
Relative Volume:
2.06
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+7.00%
1M Prestazione:
+12.98%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$12.99
$14.21
Intervallo di 1 settimana:
Value
$11.11
$14.21
Portata 52W:
Value
$11.00
$14.21

Generate Biomedicines Inc Stock (GENB) Company Profile

Name
Nome
Generate Biomedicines Inc
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
GENB's Discussions on Twitter

Compare GENB vs VRTX, REGN, ARGX, ALNY, INSM

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
GENB icon
GENB
Generate Biomedicines Inc
13.75 1.75B 0 0 0 0.00
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
438.71 111.45B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
761.85 80.54B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
746.42 46.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
318.85 42.29B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
162.43 35.01B 606.42M -1.28B -997.58M -6.403

Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-24 Iniziato Cantor Fitzgerald Overweight
2026-03-24 Iniziato Goldman Buy
2026-03-24 Iniziato Guggenheim Buy
2026-03-24 Iniziato Morgan Stanley Overweight
2026-03-24 Iniziato Piper Sandler Overweight

Generate Biomedicines Inc Borsa (GENB) Ultime notizie

pulisher
Apr 03, 2026

Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat

Apr 03, 2026
pulisher
Apr 02, 2026

Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada

Apr 02, 2026
pulisher
Mar 30, 2026

IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace

Mar 30, 2026
pulisher
Mar 27, 2026

Kailera Therapeutics files for US IPO - MarketScreener

Mar 27, 2026
pulisher
Mar 27, 2026

Flagship-backed Generate Bio seeks $425 million in US IPO - MSN

Mar 27, 2026
pulisher
Mar 27, 2026

Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - MarketBeat

Mar 27, 2026
pulisher
Mar 26, 2026

Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent

Mar 26, 2026
pulisher
Mar 25, 2026

This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm

Mar 25, 2026
pulisher
Mar 24, 2026

Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - Seeking Alpha

Mar 24, 2026
pulisher
Mar 24, 2026

The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com

Mar 24, 2026
pulisher
Mar 24, 2026

Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com

Mar 24, 2026
pulisher
Mar 24, 2026

Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - MarketScreener

Mar 24, 2026
pulisher
Mar 24, 2026

Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia

Mar 24, 2026
pulisher
Mar 24, 2026

Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com

Mar 24, 2026
pulisher
Mar 22, 2026

ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView

Mar 22, 2026
pulisher
Mar 19, 2026

Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada

Mar 19, 2026
pulisher
Mar 18, 2026

Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat

Mar 18, 2026
pulisher
Mar 17, 2026

Free cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

GENB | Generate Biomedicines, Inc. Common Stock Data, Price & News - Quiver Quantitative

Mar 17, 2026
pulisher
Mar 17, 2026

Total debt per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Revenue per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat

Mar 17, 2026
pulisher
Mar 16, 2026

Total liabilities & shareholders' equities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

After tax other income/expense of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Gross profit of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

EBIT of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Total revenue of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Average basic shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Cash per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Generate Biomedicines, Inc. Income Statement – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Generate Biomedicines, Inc. Dividends – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Net debt of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Tangible book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 16, 2026
pulisher
Mar 15, 2026

Cash from investing activities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Free cash flow of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Generate Biomedicines, Inc. Cash Flow – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Long term debt to total assets ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Total liabilities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Enterprise value to EBITDA ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 15, 2026
pulisher
Mar 14, 2026

Price to sales ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView

Mar 14, 2026

Generate Biomedicines Inc Azioni (GENB) Dati Finanziari

Non sono disponibili dati finanziari per Generate Biomedicines Inc (GENB). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$99.12
price up icon 0.49%
$28.33
price up icon 1.76%
$48.57
price up icon 0.16%
$91.18
price up icon 1.97%
ONC ONC
$310.79
price up icon 0.76%
$162.43
price down icon 1.47%
Capitalizzazione:     |  Volume (24 ore):